WO2000037094A3 - Applications therapeutiques de polypeptides flint - Google Patents

Applications therapeutiques de polypeptides flint Download PDF

Info

Publication number
WO2000037094A3
WO2000037094A3 PCT/US1999/030734 US9930734W WO0037094A3 WO 2000037094 A3 WO2000037094 A3 WO 2000037094A3 US 9930734 W US9930734 W US 9930734W WO 0037094 A3 WO0037094 A3 WO 0037094A3
Authority
WO
WIPO (PCT)
Prior art keywords
flint
mflint
fasl
therapeutic applications
fas
Prior art date
Application number
PCT/US1999/030734
Other languages
English (en)
Other versions
WO2000037094A2 (fr
Inventor
Fredric Jay Cohen
James Arthur Posada
Daniel Wierda
Original Assignee
Lilly Co Eli
Fredric Jay Cohen
James Arthur Posada
Daniel Wierda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/006797 external-priority patent/WO1999050413A2/fr
Application filed by Lilly Co Eli, Fredric Jay Cohen, James Arthur Posada, Daniel Wierda filed Critical Lilly Co Eli
Priority to JP2000589204A priority Critical patent/JP2003520761A/ja
Priority to EP99966602A priority patent/EP1140138A2/fr
Priority to CA002358508A priority patent/CA2358508A1/fr
Priority to AU22111/00A priority patent/AU2211100A/en
Publication of WO2000037094A2 publication Critical patent/WO2000037094A2/fr
Publication of WO2000037094A3 publication Critical patent/WO2000037094A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

la protéine FLINT mature (mFLINT) se lie avec FasL et LIGHT, et empêche une interaction FasL-Fas. La protéine mature mFLINT inhibe l'activité apoptotique et pro-inflammatoire à médiation FasL-Fas, et convient pour le traitement de troubles associés à une apoptose et à une inflammation anormales. L'invention concerne des séquences d'amino-acides et de nucléotides de FLINT et de FLINT mature. Elle porte également sur des compositions thérapeutiques et sur des méthodes de traitement faisant intervenir mFLINT.
PCT/US1999/030734 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint WO2000037094A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000589204A JP2003520761A (ja) 1998-12-22 1999-12-21 Ｆｌｉｎｔポリペプチドの治療用への適用
EP99966602A EP1140138A2 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint
CA002358508A CA2358508A1 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint
AU22111/00A AU2211100A (en) 1998-12-22 1999-12-21 Therapeutic applications of flint polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11340798P 1998-12-22 1998-12-22
US60/113,407 1998-12-22
PCT/US1999/006797 WO1999050413A2 (fr) 1998-03-30 1999-03-30 APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
USPCT/US99/06797 1999-03-30
US17223999P 1999-10-20 1999-10-20
US60/172,239 1999-10-20

Publications (2)

Publication Number Publication Date
WO2000037094A2 WO2000037094A2 (fr) 2000-06-29
WO2000037094A3 true WO2000037094A3 (fr) 2000-11-09

Family

ID=27378725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030734 WO2000037094A2 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint

Country Status (5)

Country Link
EP (1) EP1140138A2 (fr)
JP (1) JP2003520761A (fr)
AU (1) AU2211100A (fr)
CA (1) CA2358508A1 (fr)
WO (1) WO2000037094A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
WO2002009668A2 (fr) * 2000-08-02 2002-02-07 Eli Lilly And Company Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
GB202016058D0 (en) * 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
EP0861850A1 (fr) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Récepteurs TR4, liés à la nécrose tumorale
WO1999004001A1 (fr) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Recepteur ztnfr-5 du facteur de necrose tumorale
WO1999007738A2 (fr) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999026977A1 (fr) * 1997-11-24 1999-06-03 Biogen, Inc. Recepteurs 'opg-2'
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
EP0861850A1 (fr) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Récepteurs TR4, liés à la nécrose tumorale
WO1999004001A1 (fr) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Recepteur ztnfr-5 du facteur de necrose tumorale
WO1999007738A2 (fr) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999026977A1 (fr) * 1997-11-24 1999-06-03 Biogen, Inc. Recepteurs 'opg-2'
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. MATUTE-BELLO ET AL: "Soluble Fas Ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS)", JOURNAL OF IMMUNOLOGY., vol. 163, no. 4, 15 August 1999 (1999-08-15), BALTIMORE US, pages 2217 - 2225, XP002137439 *

Also Published As

Publication number Publication date
CA2358508A1 (fr) 2000-06-29
JP2003520761A (ja) 2003-07-08
AU2211100A (en) 2000-07-12
EP1140138A2 (fr) 2001-10-10
WO2000037094A2 (fr) 2000-06-29

Similar Documents

Publication Publication Date Title
WO1999050413A3 (fr) APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
ES2146552A1 (es) Peptidos inhibidores de tgf/31
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
HUP0103114A3 (en) Apolipoprotein a-1 agonists and their use to treat dyslipidemic disorders
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
PT1253918E (pt) Composições compreendendo modafinil para tratamento do distúrbio por défice de atenção e hiperactividade
ATE285219T1 (de) Rekombinante haarbehandlungsmittel
HK1054389A1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia.
SG160205A1 (en) Modified polypeptide
GB2367061A (en) Peptides
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
WO2000037094A3 (fr) Applications therapeutiques de polypeptides flint
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
AU1384995A (en) Human circulating cytokine cc-1
NZ333456A (en) Type-2 chemokine binding proteins and methods of use therefor
WO2003018606A3 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
WO2003087308A3 (fr) Utilisation de l'interleukine-24 pour traiter le cancer de l'ovaire
HK1047549A1 (en) Il6ril6 chimera for the treatment of neurodegeneraive diseases.
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
MXPA02001268A (es) Antagonistas de il-16.
EP1431391A3 (fr) Rantes mute et son utilisation thérapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2358508

Country of ref document: CA

Ref country code: CA

Ref document number: 2358508

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 589204

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999966602

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966602

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966602

Country of ref document: EP